Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Jesus, Loreta Zoleta-De
NCT06015282: The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older	Active, not recruiting	3	7741	Europe, Canada, US, RoW	Investigational aQIVc, licensed QIV1, licensed QIV2	Seqirus	Influenza, Human	03/24	01/25
B-Well 2, NCT05630820 / 2022-002268-53: Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B	Active, not recruiting	3	859	Europe, Canada, Japan, US, RoW	Bepirovirsen, Placebo	GlaxoSmithKline, GlaxoSmithKline Research & Development Limited	Chronic Hepatitis B, Hepatitis B, Chronic	11/25	05/26
NCT05769049: The Safety and Immunogenicity Study of the Recombinant Zoster Vaccine (CHO Cell)	Completed	1	48	RoW	REC610, Recombinant Zoster Vaccine (CHO cell), Shingrix	Jiangsu Rec-Biotechnology Co., Ltd.	Herpes Zoster	12/23	12/23